ClaudiaTMartorellMDMPH FACP(She/Her)

Infectious Disease • Springfield, MA

HIV/AIDS Medicine, Mycobacterial Disease, STD Medicine

Director and Principal Investigator, The Research Institute

Join to view full profile

Dr. Martorell is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Martorell's full profile

Already have an account?

Office
57 Mulberry St.
Springfield, MA 01105
Phone+1 413-747-5566

Fax+1 413-747-5666

Summary

Board Certified Infectious Diseases Physician; MPH
Clinical Investigator in HIV/HCV/PreP/STI/other

Expertise: Infectious Diseases, HIV/HCV, HBV, STI ,PreP, DoxyPEP, Gender Affirming Care, Substance Use,Disease Prevention/Public Health, Health Care Management, Health Policy/Minority Health Policy, Minority Health Care, Health Care Disparities, CME Education, Consulting, and Clinical Research

Clinical Expertise

Viral hepatitides, Hepatitis C, Skin infections, Herpes zoster, Lyme disease, Pneumonia, Sinusitis, Clostridium difficile colitis, Helicobacter pylori infection, Urinary tract infections, HIV/AIDS, Tick-borne diseases, Influenza, Fungal infections, Bacterial vaginosis, Mycobacterial infections, Public health, Sexually transmitted disease screening, Infectious disease, Women's health, Osteomyelitis, Sexually transmitted infections, Health policy, Telemedicine, Healthcare disparities, Minority health, Substance abuse, Opiate dependence, Vaccines, Methicillin-resistant staphylococcus aureus, Bacterial vaginitis, Transgender Care, PrEP, Infusion Therapy, COVID-19, DoxyPEP, USCIS- Civil Surgeon I-693, Long Term Injectable ART

Education & Training

Harvard UniversityFellowship Health Policy, Fellowship in Minority Health Policy, 2003 - 2004
Harvard School of Public HealthMPH, Health Care Management, 2003 - 2004
UMass Chan - BaystateFellowship, Infectious Disease, 2003
UMass Chan - BaystateResidency, Internal Medicine, 1998 - 2001
University of Puerto RicoInternship, Internal Medicine, 1998 - 1999
University of Puerto Rico School of MedicineClass of 1998

Certifications & Licensure

FL State Medical License 2023 - 2027
MA State Medical License 2003 - 2026
American Board of Internal Medicine Infectious Disease

Awards, Honors, & Recognition

Antonia Pantoja Award Latino Scholarship Association, 2011
Women of Color Community Service Award 2009
Severo Ochoa Award for outstanding contribution to eradicating HIV/AIDS in the Minority Population National Minority Health Month Foundation and American Medical Association, 2007
Foundation Excellence in Medicine Award AMA- American Medical Association, 2004
Young Physician Leadership Award Hampden District Medical Society- Massachusetts Medical Society, 2003
CMS Meaningful Use Stage 1 Certification Care360 EHR, MedPlus, 2013
Join now to see all

Clinical Trials

Observational Prospective Registry of the Efficacy, Safety, and Adherence to Infergen® in Patients Infected With Hep C Start of enrollment: 2009 Aug 01
Withdrawn
Study to Determine the Effectiveness of Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) Infected Patients Who Have Previously Failed Standard of Care Start of enrollment: 2009 Dec 01
Completed
Phase 2
Study of BMS-650032 With Peginterferon Alfa-2a Plus Ribavirin Start of enrollment: 2010 Feb 01
Completed
Phase 2
Study of Daclatasvir (BMS-790052) Add-on to Standard of Care in Treatment- naïve Patients Start of enrollment: 2010 Jul 01
Completed
Phase 2
Efficacy and Safety of Adding Alisporivir (DEB025) to Peginterferon (IFN) Alfa-2a (Peg-IFN Alfa-2a) and Ribavirin in Chronic HCV Genotype 1 Patients Who Relapsed or Did Not Respond to Previous Treatment Start of enrollment: 2010 Aug 01
Completed
Phase 2
Ph IIA Study (SOC +/- NS5B) Start of enrollment: 2010 Oct 01
Completed
Phase 2
Efficacy and Safety of Alisporivir Alone or Combined With RBV or PEG in Chronic Hepatitis C Genotype 2 and 3 Treatment-naïve Participants Start of enrollment: 2010 Oct 01
Completed
Phase 2
Study to Evaluate the Safety and Efficacy of a Single Tablet Regimen of Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate Compared With a Single Tablet Regimen of Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naive Adults Start of enrollment: 2011 Feb 01
Completed
Phase 3
Long-term Observational Study in HIV Subjects Exposed to EGRIFTA® Start of enrollment: 2013 Feb 01
Terminated
Collection of Plasma and Serum Samples From Individuals Initiating Sofosbuvir for Chronic Hepatitis C for Testing Start of enrollment: 2014 Feb 01
Completed
Collection of Samples for the Clinical Evaluation of the Aptima HBV (Hepatitis B Virus) Quant (Quantification) Assay Start of enrollment: 2014 Mar 01
Completed
A Multicenter Study to Evaluate a Borrelia Diagnostic Test in Subjects With Early Stage or Late Stage Lyme Disease Start of enrollment: 2016 Apr 01
Terminated
Not Applicable
Switching to a Fixed Dose Combination of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in Human Immunodeficiency Virus Type 1 (HIV-1) Infected Adults Who Are Virologically Suppressed Start of enrollment: 2017 Jun 12
Completed
Phase 3
Digimeds to Optimize Adherence in Patients With Hepatitis C and Increased Risk for Nonadherence Start of enrollment: 2017 Jul 21
Active, not recruiting
Not Applicable
Lyme Test Indication Combinations (LyTIC) Study Start of enrollment: 2017 Jun 08
Terminated
Study to Evaluate Switching From a Regimen of Two Nucleos(t)Ide Reverse Transcriptase Inhibitors (NRTI) Plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), in Virologically-Suppressed, HIV-1 Infected African American Participants Start of enrollment: 2018 Aug 28
Completed
Phase 3
Effects of Crofelemer on the Gut Microbiome in Healthy Volunteers and in HIV+ Patients With Non-Infectious Diarrhea Start of enrollment: 2019 Oct 22
Completed
Phase 4
A Prospective and Retrospective Observational Study of Multidrug-Resistant Patient Outcomes With and Without Ibalizumab Start of enrollment: 2022 Mar 22
Recruiting
Study to Assess the Efficacy of Baloxavir Marboxil Versus Placebo to Reduce Onward Transmission of Influenza A or B in Households Start of enrollment: 2019 Oct 10
Completed
Phase 3
A Study to Assess Change in Disease Activity, Adverse Events, and How the Drug Moves Through the Body in Adult Participants Living With Human Immunodeficiency Virus (HIV) Receiving Intravenous (IV) Infusion of Budigalimab and/or ABBV-382 Start of enrollment: 2023 Oct 12
Recruiting
Phase 2
Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With Biktarvy Start of enrollment: 2024 Mar 25
Recruiting
Phase 3
Join now to see all

Publications & Presentations

PubMed

Impacts of a multipronged initiative with community HIV clinics to support retention and re-engagement in HIV care.
Ellen Eaton, Claudia T Martorell, Jewel Sawyer, Tanya S Schreibman, Gregory S Felzien
HIV Research & Clinical Practice. 2025-12-01
1 citations
HIV-1 infection kinetics, drug resistance, and long-term safety of pre-exposure prophylaxis with emtricitabine plus tenofovir alafenamide (DISCOVER): week 144 open-lab...
David A Wohl, Christoph D Spinner, Jason Flamm, C Bradley Hare, Susanne Doblecki-Lewis
The Lancet. HIV. 2024-08-01
2 citations
Switch to bictegravir/emtricitabine/tenofovir alafenamide from dolutegravir-based therapy.
Chloe Orkin, Andrea Antinori, Jürgen K Rockstroh, Santiago Moreno-Guillén, Claudia T Martorell
AIDS. 2024-06-01

Journal Articles

Switching to Coformulated Rilpivirine (RPV), Emtricitabine (FTC) and Tenofovir Alafenamide from Either RPV, FTC and Tenofovir Disoproxil Fumarate (TDF) or Efavirenz, F...
E S Daar, O Osiyemi, D Porter, M Thompson, C Martorell, HIV Medicine

Press Mentions

Healthcare Watch November 2022November 22nd, 2022
Sermo Surveys Reveals 87% of Global Physicians Feel There Is a Lack of Clinical Guidelines on How to Treat Long Covid in Patients SOctober 12th, 2022